TME Pharma N.V. (ALTME) - Total Assets
Based on the latest financial reports, TME Pharma N.V. (ALTME) holds total assets worth €2.14 Million EUR (≈ $2.50 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can TME Pharma N.V. service its debt to assess how comfortably operating cash covers total debt obligations.
TME Pharma N.V. - Total Assets Trend (2014–2025)
This chart illustrates how TME Pharma N.V.'s total assets have evolved over time, based on quarterly financial data. See net assets of TME Pharma N.V. for net asset value and shareholders' equity analysis.
TME Pharma N.V. - Asset Composition Analysis
Current Asset Composition (December 2025)
TME Pharma N.V.'s total assets of €2.14 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 94.1% |
| Accounts Receivable | €22.00K | 1.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.00K | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how TME Pharma N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALTME company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TME Pharma N.V.'s current assets represent 99.2% of total assets in 2025, an increase from 66.9% in 2014.
- Cash Position: Cash and equivalents constituted 94.1% of total assets in 2025, up from 49.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
TME Pharma N.V. Competitors by Total Assets
Key competitors of TME Pharma N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
TME Pharma N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.57 | 1.88 | 3.63 |
| Quick Ratio | 0.57 | 1.88 | 3.58 |
| Cash Ratio | 0.00 | 1.81 | 3.56 |
| Working Capital | €-1.60 Million | €1.57 Million | €7.63 Million |
TME Pharma N.V. - Advanced Valuation Insights
This section examines the relationship between TME Pharma N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.15 |
| Latest Market Cap to Assets Ratio | 3.15 |
| Asset Growth Rate (YoY) | -37.2% |
| Total Assets | €2.14 Million |
| Market Capitalization | $6.73 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TME Pharma N.V.'s assets at a significant premium (3.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: TME Pharma N.V.'s assets decreased by 37.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TME Pharma N.V. (2014–2025)
The table below shows the annual total assets of TME Pharma N.V. from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.14 Million ≈ $2.50 Million |
-37.20% |
| 2024-12-31 | €3.41 Million ≈ $3.98 Million |
+36.73% |
| 2023-12-31 | €2.49 Million ≈ $2.91 Million |
-52.47% |
| 2022-12-31 | €5.24 Million ≈ $6.13 Million |
-46.35% |
| 2021-12-31 | €9.77 Million ≈ $11.42 Million |
-8.32% |
| 2020-12-31 | €10.65 Million ≈ $12.46 Million |
+515.13% |
| 2019-12-31 | €1.73 Million ≈ $2.02 Million |
-61.66% |
| 2018-12-31 | €4.52 Million ≈ $5.28 Million |
+386.33% |
| 2017-12-31 | €929.00K ≈ $1.09 Million |
-67.62% |
| 2016-12-31 | €2.87 Million ≈ $3.35 Million |
-52.51% |
| 2015-12-31 | €6.04 Million ≈ $7.06 Million |
+95.50% |
| 2014-12-31 | €3.09 Million ≈ $3.61 Million |
-- |
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more